Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting
Peer reviewed, Journal article
Permanent lenke
http://hdl.handle.net/11250/2446262Utgivelsesdato
2017Metadata
Vis full innførselSamlinger
- Artikler [5061]
- Publikasjoner fra CRIStin FHI [7531]